A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
Price : $35 *
At a glance
- Drugs Mocravimod (Primary)
- Indications Transplant rejection
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 06 Nov 2018 Status changed from active, no longer recruiting to completed.
- 22 Mar 2018 Planned End Date changed from 25 Jan 2020 to 24 Aug 2018.
- 22 Mar 2018 Planned primary completion date changed from 25 Jan 2020 to 24 Aug 2018.